Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 8/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17234417 | 0.89 | HPGDS (0.42) | HPGDSUSP30KDM4EPKMCKS1B | |
| SCHEMBL17224179 | 0.89 | HPGDS (0.42) | HPGDSUSP30KDM4EPKMCKS1B | |
| SCHEMBL17224933 | 0.87 | PDE2A (0.41) | HPGDSUSP30KDM4EPKMGPR119 | |
| SCHEMBL18489085 | 0.86 | PDE2A (0.40) | USP30KDM4EPDE2A | |
| SCHEMBL17224917 | 0.86 | MALT1 (0.40) | HPGDSUSP30PDE2A | |
| SCHEMBL17224958 | 0.86 | HPGDS (0.40) | HPGDSUSP30KDM4EPKMPDE2A | |
| SCHEMBL503579 | 0.86 | USP30 (0.43) | HPGDSUSP30KDM4EPKMGPR119 | |
| SCHEMBL1990004 | 0.86 | USP30 (0.43) | HPGDSUSP30KDM4EPKMGPR119 | |
| SCHEMBL503578 | 0.86 | USP30 (0.43) | HPGDSUSP30KDM4EPKMGPR119 | |
| SCHEMBL12695288 | 0.85 | HPGDS (0.41) | HPGDSUSP30KDM4EPKMCKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3137459-B1 | MORPHOLIN-PYRIDINE DERIVATIVES HAVING AFFINITY TO THE TAAR1 RECEPTOR | HOFFMANN LA ROCHE (CH) | 2018-05-23 | — | — | EP | disclosed |
| US-9840501-B2 | Morpholin-pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-12-12 | — | — | US | disclosed |
| EP-3137459-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-03-08 | — | — | EP | disclosed |
| US-20170044145-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-02-16 | — | — | US | disclosed |
| WO-2015165085-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015165835-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044145-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | OPRM1, MC2R, OPRL1 | HPGDS 3970/4885USP30 4469/4885KDM4E 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.